Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2002
10/31/2002WO2002066650A3 Streptococcus pyogenes polypeptides and corresponding dna fragments
10/31/2002WO2002064574A3 Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods
10/31/2002WO2002064161A9 Method and compositions for immunization with the pseudomonas v antigen
10/31/2002WO2002061105A9 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
10/31/2002WO2002060949A3 Glycoforms a fas ligand inhibitory protein analog
10/31/2002WO2002059148A9 A method for identification, isolation and production of antigens to a specific pathogen
10/31/2002WO2002053185A3 Anti-inflammatory use of polycationic compounds
10/31/2002WO2002051356A3 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
10/31/2002WO2002049650A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/31/2002WO2002047700A9 Composite & making method of medicines for cold treatment
10/31/2002WO2002042412A3 Protease inhibitors and their pharmaceutical uses
10/31/2002WO2002042315A3 Macrolide solvates
10/31/2002WO2002040474A3 Heterocyclylalkyl piperidine derivatives and their use as antimicrobial agents
10/31/2002WO2002022611A3 Caspase inhibitors and uses thereof
10/31/2002WO2002020045A3 Vaccine against microbial pathogens
10/31/2002WO2002015842A3 Process for preparation of anhydrous azithromycin
10/31/2002WO2002008434A3 Bicistronic influenza comprising two genes in tandem
10/31/2002WO2002004002A3 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
10/31/2002WO2002000250A3 Hiv-1 vaccines and screening methods therefor
10/31/2002WO2001087348A3 Multifunctional nanodevice platform
10/31/2002WO2001057072A3 Pharmacologically active antiviral peptides and methods of their use
10/31/2002WO2001053342A9 Chimeric prostate-homing peptides with pro-apoptotic activity
10/31/2002WO2001047962A8 Attenuated microorganisms for the treatment of infection
10/31/2002WO2000062766A3 Uses of ppar-gamma agonists in neutrophil-induced diseases
10/31/2002US20020161221 Ether type lipid a 1-carboxylic acid analogs
10/31/2002US20020161053 Inflammatory cytokine production inhibitors, matrix metalloprotease production inhibitors, inflammatory cell adhesion molecules incidence inhibitors, antiinflammatory agents
10/31/2002US20020161035 Medicaments for chemotherapeutic treatment of disease
10/31/2002US20020161033 Substituted 1,5-dihydropyrrol-2-one derivatives active as NMDA receptor antagonists for treatment of states of pain
10/31/2002US20020161029 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
10/31/2002US20020161024 Administering 2-(piperidin-2,6-dion-3-yl),4-amino-isoindolin-1-one to treat an eye condition
10/31/2002US20020161014 Purinyl substituted quinazoline-4-one derivatives
10/31/2002US20020161006 1,4-dihydropyridine compounds as bradykinin antagonists
10/31/2002US20020161004 Antiinflammation agents
10/31/2002US20020160987 Novel 4-dedimethylaminotetracycline derivatives
10/31/2002US20020160980 Method of treating hepatitis delta virus infection
10/31/2002US20020160974 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/31/2002US20020160969 Nucleosides and oligonucleotides containing boron clusters
10/31/2002US20020160962 Non-structural protein 3 (NS3), part of a hepatitis C virus protease necessary for polypeptide processing and viral replication; alpha-ketoamide compounds of given formula
10/31/2002US20020160948 Such as preventing or treating primary cancer cell growth
10/31/2002US20020160942 Echinocandin/carbohydrate complexes
10/31/2002US20020160940 Modulation of endogenous gene expression in cells
10/31/2002US20020160932 Enzyme complex; treatment and prophylaxis of herpes infections; sulfonamide compounds of given formula
10/31/2002US20020160481 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
10/31/2002US20020160447 Ups (ugc)
10/31/2002US20020160393 Controlling gene expression in eukaryotic cells
10/31/2002US20020160383 Use of nucleic acid analogues in diagnostics and analytical procedures
10/31/2002US20020160379 Gapped 2' modified oligonucleotides
10/31/2002US20020160044 Liver selective drug therapy
10/31/2002US20020160039 Infusing lipid/alcohol solution directly into aqueous polymer solution; resulting liposome which may be incorporated with a pharmaceutical substance consists of multilamellar vesicles of average size of 1-8 microns
10/31/2002US20020160020 Enterohemorrhagic escherichia coli vaccine
10/31/2002US20020160019 Providing peptide that bears a DR motif corresponding to a Class II HLA molecule, testing peptide for binding affinity to a Class II HLA DR molecule, whereupon an IC50 binding affinity is determined
10/31/2002US20020160018 For inducing in a bovine host an immunological response against bovine respiratory syncytial virus or bovine viral diarrhea virus
10/31/2002US20020160016 Modified surface antigen
10/31/2002US20020160015 Chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes and its uses
10/31/2002US20020160011 Adjuvant compositions for vaccines
10/31/2002US20020160000 PD-1, a receptor for B7-4, and uses therefor
10/31/2002US20020159996 Use of CD23 antagonists for the treatment of neoplastic disorders
10/31/2002US20020159976 An isolated polynucleotide comprising a nucleotide sequence present in Lactobacillus rhamnosus strain HN001 that encodes a polypeptide having atleast one enzymetic activity; genetic engineering
10/31/2002US20020159956 Providing a chewing gum, includes a gum center and a coating coverings, coating includes a drug designed to be delivered into systemic system of indivisual
10/31/2002EP1232171A4 Method of preparing clarithromycin
10/31/2002DE10121113A1 Genmodifizierte YT Zelllinie und ihre Verwendung Genetically Modified YT cell line and their use
10/31/2002DE10120627A1 Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren Use of Phyllanthus for the treatment or prophylaxis of infections caused by hepatitis B viruses
10/31/2002CA2445888A1 Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
10/31/2002CA2445740A1 Use of metals to treat inflammatory skin conditions
10/31/2002CA2445734A1 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
10/31/2002CA2445729A1 Use of metals to treat mucosal membranes
10/31/2002CA2445389A1 Antimicrobial polymeric surfaces
10/31/2002CA2445255A1 Vhh single heavy chain antibody and a method for its preparation in a mammal
10/31/2002CA2445233A1 Phthalazinones derivatives useful as pde4/7 inhibitors
10/31/2002CA2445188A1 Arylindenopyridines with pde inhibiting activity
10/31/2002CA2445179A1 Identification of essential genes of aspegillus fumigatus and methods of use
10/31/2002CA2445114A1 Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same
10/31/2002CA2444885A1 Methods and compositions for treating oral and esophageal lesions
10/31/2002CA2444883A1 Microprojection array having a beneficial agent containing coating
10/31/2002CA2444747A1 Smallpox vaccine
10/31/2002CA2444675A1 Secreted proteins
10/31/2002CA2444599A1 Melanocortin receptor ligands
10/31/2002CA2444570A1 Tricyclic compounds useful as hiv reverse transcriptase inhibitors
10/31/2002CA2444471A1 Synthesis of pancratistatin prodrugs
10/31/2002CA2444235A1 New polynucleotides and polypeptides of the ifn.alpha.-17 gene
10/31/2002CA2444006A1 Expression of core-glycosylated hcv envelope proteins in yeast
10/31/2002CA2443781A1 Core-glycosylated hcv envelope proteins
10/31/2002CA2443740A1 Constructs and methods for expression of recombinant hcv envelope proteins
10/31/2002CA2443600A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002CA2443587A1 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/31/2002CA2443518A1 Controlled release particles
10/31/2002CA2443373A1 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002CA2441540A1 Replikin peptides and uses thereof
10/31/2002CA2439959A1 A method for the preparation of oxazolidinones
10/30/2002EP1253201A2 Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor
10/30/2002EP1253153A1 Process for preparing 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin A derivatives
10/30/2002EP1252888A1 Biologically active labdane or labdene derivatives from Cistus
10/30/2002EP1252323A2 Virus strains for the oncolytic treatment of cancer
10/30/2002EP1252322A2 Herpes virus strains for gene therapy
10/30/2002EP1252188A2 G-protein coupled receptors
10/30/2002EP1252182A1 PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
10/30/2002EP1252179A2 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them
10/30/2002EP1252178A1 Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
10/30/2002EP1252163A2 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
10/30/2002EP1252162A1 Alpha v integrin receptor antagonists
1 ... 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 ... 1798